ChemicalBook
Chinese Japanese Germany Korea

Ofloxacin

Ofloxacin
Ofloxacin structure
CAS No.
82419-36-1
Chemical Name:
Ofloxacin
Synonyms
oflx;pt01;Oflox;floxin;Exocin;Floxil;hoe280;Visren;Floxal;TARIVID
CBNumber:
CB7103599
Molecular Formula:
C18H20FN3O4
Formula Weight:
361.37
MOL File:
82419-36-1.mol

Ofloxacin Properties

Melting point:
270-2750C
Boiling point:
571.5±50.0 °C(Predicted)
Density 
1.2688 (estimate)
storage temp. 
2-8°C
solubility 
1 M NaOH: soluble50mg/mL
form 
neat
pka
5.19±0.40(Predicted)
color 
Colorless needles from ethanol
Water Solubility 
Soluble in acetic acid or water. Slightly soluble in methanol
λmax
326nm(H2O)(lit.)
Merck 
14,6771
CAS DataBase Reference
82419-36-1(CAS DataBase Reference)
NCI Dictionary of Cancer Terms
ofloxacin
FDA UNII
A4P49JAZ9H
EPA Substance Registry System
Ofloxacin (82419-36-1)
SAFETY
  • Risk and Safety Statements
Hazard statements  H303
Hazard Codes  Xn,Xi
Risk Statements  22-42/43-68-36/37/38
Safety Statements  26-36/37/39-24/25-22-37/39-60
WGK Germany  3
RTECS  UU8815550
HS Code  29349990
Toxicity LD50 in male, female mice, male, female rats (mg/kg): 5450, 5290, 3590, 3750 orally; 208, 233, 273, 276 i.v.; >10000, >10000, 7070, 9000 s.c. (Ohno)

Ofloxacin price More Price(13)

Manufacturer Product number Product description CAS number Packaging Price Updated Buy
Sigma-Aldrich 33703 Ofloxacin VETRANAL 82419-36-1 100mg-r $56.1 2020-08-18 Buy
Sigma-Aldrich O8757 Ofloxacin fluoroquinolone antibiotic 82419-36-1 1g $77.6 2020-08-18 Buy
TCI Chemical O0403 Ofloxacin >98.0%(HPLC)(T) 82419-36-1 5g $81 2020-06-24 Buy
TCI Chemical O0403 Ofloxacin >98.0%(HPLC)(T) 82419-36-1 25g $268 2020-06-24 Buy
Alfa Aesar J62080 Ofloxacin 82419-36-1 5g $122 2020-06-24 Buy

Ofloxacin Chemical Properties,Uses,Production

Description

Ofloxacin is an antibacterial agent with increased potency in comparison to the prototype third generation quinolone, norfloxacin. It has a broad spectrum of activity against gram-positive and gram-negative bacteria and is useful in the treatment of kidney, genitourinary, and upper respiratory tract infections.

Chemical Properties

Off-White Solid

Originator

Daiichi Seiyaku (Japan)

Uses

Fluorinated quinolone antibacterial

Definition

ChEBI: An oxazinoquinolone carrying carboxy, fluoro, methyl and 4-methylpiperazino substituents. A synthetic fluoroquinolone antibacterial agent, it inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.

Manufacturing Process

20 g of 2,3,4-trifluoronitrobenzene was dissolved in 150 ml of dimethyl sulfoxide, and to this mixture a solution of 10% potassium hydroxide was added dropwise while keeping the temperature at 18° to 20°C. Then, the mixture was stirred for 2 hours at room temperature and one liter of water was added to this reaction mixture and the mixture was shaken with chloroform. The water layer was acidified with hydrochloric acid and was extracted with chloroform. The extract was washed with water and was dried, then chloroform layer was concentrated. The residue was purified by silica gel column chromatography to provide 5.8 g of 2,3-difluoro-6-nitrophenol as yellow oil.
7.9 g of the 2,3-difluoro-6-nitrophenol, 50.1 g of 1,2-dibromoethane and 18.7 g of potassium carbonate were added to 80 ml of dimethylformamide and the mixture was stirred for 2.5 hours at from about 80° to 100°C (bath temperature). The reaction mixture was concentrated to dryness in vacuo and the residue was distributed between ethyl acetate and water. The organic solvent layer was washed with water and was dried, then the solvent was evaporated. The residue was dissolved in benzene and was purified by silica gel column chromatography to provide 7.7 g of 2-(2-bromoethoxy)-3,4difluoronitrobenzene as light yellow oil.
1.74 g of this product was dissolved in 30 ml of methanol and a solution of 6.44 g of sodium dithionite dissolved in 15 ml of water was added thereto. The mixture was stirred for 1 hour at room temperature. Methanol was evaporated and the residue was extracted with chloroform. After the extract was washed with water and dried, the solvent was evaporated to provide 0.44 g of 2-(2-bromoethoxy)-3,4-difluoroaniline.
1.82 g of this product and 3.03 g of potassium carbonate were added to 10 ml of dimethylformamide and the mixture was stirred for 1 hour at from about 80° to 100°C (bath temperature). The reaction mixture was added to ice-cold water and was extracted with ethyl acetate. After the extract was washed with water and dried, the solvent was distilled off at room temperature to provide 1.21 g of 7,8-difluoro-2,3-dihydro-4H-[1,4]benzoxazine with m.p. 48°-54°C.
The mixture of 1.1 g of this product and 1.38 g of diethyl ethoxymethylenemalonate was stirred for 2 hours at from about 130° to 135°C (bath temperature). The ethanol produced was evaporated and 20 g of ethyl polyphosphate was added to the residue. Then the mixture was stirred for 1.5 hours at from about 140° to 145°C (bath temperature). The reaction mixture was added to ice-cold water and was extracted with chloroform. The extract was washed fully with water. After drying, the solvent was evaporated and the residue was recrystallized from ethyl acetate. 1.3 g of ethyl 9,10difluoro-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzoxazine-6carboxylate was obtained as colorless needles with m.p. 265°-266°C.
1.15 g of this product was added to 12 ml of mixture of concentrated hydrochloric acid and acetic acid (1:4 by volume) and the mixture was stirred for 4 hours at 100° to 110°C (bath temperature). After cooling, the precipitated crystals were collected by filtration, washed with water, methanol and chloroform to give 0.78 g of 9,10-difluoro-7-oxo-2,3-dihydro-7Hpyrido[1,2,3-de][1,4]-benzoxazine-6-carboxylic acid as colorless needles with m.p. above 300°C.
1.0 g of 9,10-difluoro-3-methyl-7-oxo-2,3-dihydro-7H-pyrido[1,2,3de][1,4]benzoxazine-6-carboxylic acid and 2.85 g of N-methylpiperazine were added to 15 ml of dimethylsulfoxide. The mixture was stirred at a temperature of from about 100° to 110°C (bath temperature) for 12 hours and the reaction mixture was concentrated to dryness in vacuo and 40 ml of water was added to the residue. Then the product was extracted with chloroform. The extract was dried and concentrated to dryness in vacuo. The residue was recrystallized from ethanol to provide 550 mg of 9-fluoro-3-methyl-10-(4methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H-pyrido[1,2,3de][1,4]benzoxazine-6-carboxylic acid as colorless needles with m.p. 250°257°C (with decomposition).

brand name

Floxin (Ortho-McNeil); Floxin (Daiichi Pharmaceutical); Ocuflox (Allergan);TARIVID.

Therapeutic Function

Antibacterial

Antimicrobial activity

It exhibits good activity against a wide range of enterobacteria, including strains resistant to nalidixic acid, as well as against Aeromonas, Campylobacter, Vibrio and Moraxella spp. Activity against methicillin-sensitive Staph. aureus is good, but streptococci, including Str. pneumoniae and enterococci, are less susceptible. Most anaerobes are moderately or completely resistant. It is active against L. pneumophila, Ch. pneumoniae, C. trachomatis, mycoplasmas, ureaplasmas and M. tuberculosis. Other mycobacteria such as M. fortuitum, M. kansasii, M. chelonei and the M. avium complex are moderately susceptible.

Pharmaceutical Applications

A tricyclic 6-fluoro, 7-piperazinyl quinoline with a methyl substituted oxazine ring substituted. It is a racemic mixture of l- (levofloxacin, see p. 319) and d-isomers.

Biotechnological Applications

Ofloxacin is a fluoroquinolone antibiotic present as a racemic mixture. Levofloxacin, S-isomer of ofloxacin, shows a broad spectrum of antibacterial activity against both gram-positive and gram-negative bacteria. The antibacterial activity of levofloxacin is 8–128 times greater than that of the corresponding R-isomer. A novel esterase of type B1 carboxylesterase/lipase family from a marine isolate Y. lipolytica CL180 was used to resolve a racemic mixture of ofloxacin ester. This esterase showed an enantioselectivity toward R, S-ofloxacin ester, and levofloxacin was produced with an enantiomeric excess of 52 % (Kim et al. 2007).

Pharmacokinetics

Oral absorption: c. 95%
Cmax400 mg oral: 3–5 mg/L after 1–1.5 h
200 mg intravenous (30-min infusion): 1.8 mg/L 1 h after end infusion
Plasma half-life: 5–7 h
Volume of distribution: 1–2.5 L/kg
Plasma protein binding: c. 25%
absorption and distribution
There is no significant interference with absorption by magnesium–aluminum hydroxide or calcium carbonate compounds,providing administration is separated by at least 2 h. In patients receiving repeated 200 mg doses, the mean peak plasma concentration rose from 2.7 mg/L after the first dose to 3.4 mg/L after the seventh.
It is widely distributed, achieving levels ≥50% of simultaneous plasma concentrations in many tissues, including lung and bronchial secretions. In cantharides and suction blisters, peak concentrations exceed those in plasma, while the elimination half-life is similar. In patients with non-inflamed meninges, 200 mg administered orally or by intravenous infusion over 30 min produced CSF concentrations of around 0.4–1 mg/L at 2–4 h while the plasma concentration was 1.7–4 mg/L: a 400 mg intravenous infusion yielded a CSF concentration of 2 mg/L, which is adequate for some Gram-negative bacteria, but not for Gram-positive bacteria or Ps. aeruginosa.
Metabolism and excretion
It is poorly metabolized into desmethyl and N-oxide derivatives (<5% of the administered dose), only about 20% of a dose being eliminated by non-renal routes. There is a very slight effect on cytochrome P450-related isoenzymes and no significant effect on the metabolism of theophylline in dosages of up to 800 mg.
About 60% of a dose appears in the urine over 12 h and 80–90% over 48 h. The apparent elimination half-life is prolonged in renal failure, reaching 30–50 h in anuria, necessitating a dosage reduction. The desmethyl metabolite accumulates in all patients and the N-oxide in 50%. Absorption and distribution are not affected by renal failure. Significant amounts of the drug appear in the feces, producing very variable concentrations up to 100 mg/kg.

Clinical Use

9-Fluoro-2,3-dihydro-3-methyl-10(4-methyl-1-piperazin-yl)-7-oxo-7H-pyrido[1,2,3-de]-1,4,-benzoxazine-6-carboxylicacid (Floxin, Floxin IV) is a member of the quinolone class of antibacterial drugs wherein the 1- and 8-positions are joined in the form of a 1,4-oxazine ring.
Ofloxacin has been approved for the treatment of infectionsof the lower respiratory tract, including chronic bronchitisand pneumonia, caused by Gram-negative bacilli. It isalso used for the treatment of pelvic inflammatory diseaseand is highly active against both gonococci and chlamydia.In common with other fluoroquinolones, ofloxacin is not effectivein the treatment of syphilis. A single 400-mg oraldose of ofloxacin in combination with the tetracycline antibioticdoxycycline is recommended by the Centers forDisease Control and Prevention (CDC) for the outpatienttreatment of acute gonococcal urethritis. Ofloxacin is alsoused for the treatment of urinary tract infections caused byGram-negative bacilli and for prostatitis caused by E. coli.Infections of the skin and soft tissues caused by staphylococci,streptococci, and Gram-negative bacilli may also betreated with ofloxacin.

Clinical Use

Complicated and uncomplicated infections of the urinary tract, chronic prostatitis
Uncomplicated urogenital and anorectal gonorrhea (single-dose), chancroid (3-day course), genital chlamydial infections (7-day course) Lower respiratory tract infections, including bronchopneumonia, community-acquired pneumonia (except pneumococcal pneumonia), acute bacterial exacerbations of chronic bronchitis (unless pneumococci are involved) and bronchiectasis
Enteric fever, including the chronic carrier state; gastroenteritis caused by enterotoxigenic Escherichia coli, Salmonella, Shigella and Campylobacter spp. Ocular infections (ophthalmic preparation)

Side effects

Untoward reactions havebeen described in 2.5–7.5% of patients, and are those common to the group: gastrointestinal tract disturbances, rashes, tendon rupture and insomnia. CNS effects rarely occur.

Safety Profile

Poison by intravenous route.Moderately toxic by ingestion. An experimental teratogen.Other experimental reproductive effects. Human systemiceffects: body temperature increase, diarrhea,hallucinations, hypermotility, irritability, psychosis.Mutation d

Ofloxacin Preparation Products And Raw materials

Raw materials

Preparation Products


Ofloxacin Suppliers

Global( 379)Suppliers
Supplier Tel Fax Email Country ProdList Advantage
Henan DaKen Chemical CO.,LTD.
+86-371-55531817
info@dakenchem.com CHINA 21842 58
Henan Tianfu Chemical Co.,Ltd.
0371-55170693
0371-55170693 info@tianfuchem.com CHINA 22625 55
PI & PI BIOTECH INC.
18371201331
020-81716319 Sales@pipitech.com CHINA 3048 55
Hubei XinRunde Chemical Co., Ltd.
+8615102730682
02783214688 bruce@xrdchem.cn CHINA 568 55
career henan chemical co
+86-371-86658258
sales@coreychem.com CHINA 30039 58
Hubei Jusheng Technology Co.,Ltd.
86-18871470254
027-59599243 linda@hubeijusheng.com CHINA 28231 58
QUALITY CONTROL CHEMICALS INC.
(323) 306-3136
(626) 453-0409 orders@qcchemical.com United States 8406 58
Xiamen AmoyChem Co., Ltd
+86 592-605 1114
sales@amoychem.com CHINA 6371 58
BOC Sciences
1-631-619-7922 1-631-619-7922
1-631-614-7828 inquiry@bocsci.com United States 20039 58
Chongqing Chemdad Co., Ltd
+86-13650506873
sales@chemdad.com CHINA 35434 58

View Lastest Price from Ofloxacin manufacturers

Image Release date Product Price Min. Order Purity Supply Ability Manufacturer
2020-05-12 Ofloxacin
82419-36-1
US $0.01-1.00 / KG 1KG 99% 50 tons Shaanxi Dideu Medichem Co. Ltd
2018-12-17 Ofloxacin
82419-36-1
US $7.00 / kg 1kg 99% 100KG career henan chemical co
2018-09-25 Active Pharmaceutical Ingredients Ofloxacin quinolone antibacterial drugs CAS 82419-36-1
82419-36-1
US $1.00 / KG 10G 99% 10MT Hubei XinRunde Chemical Co., Ltd.

82419-36-1(Ofloxacin)Related Search:


Copyright 2017 © ChemicalBook. All rights reserved